BeOne Medicines (NASDAQ:ONC - Get Free Report) had its price objective raised by JPMorgan Chase & Co. from $317.00 to $321.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price target suggests a potential upside of 32.61% from the company's current price.
Several other equities analysts have also commented on ONC. Wall Street Zen raised BeOne Medicines from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Sanford C. Bernstein set a $259.00 target price on shares of BeOne Medicines in a research report on Thursday, March 13th. Guggenheim raised their price target on shares of BeOne Medicines from $348.00 to $350.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Macquarie lifted their price target on shares of BeOne Medicines from $259.00 to $313.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. Finally, Royal Bank Of Canada raised shares of BeOne Medicines from an "outperform" rating to a "moderate buy" rating and set a $311.00 price objective for the company in a research report on Friday. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, BeOne Medicines presently has a consensus rating of "Buy" and a consensus target price of $320.67.
View Our Latest Stock Report on ONC
BeOne Medicines Stock Performance
Shares of NASDAQ:ONC traded up $0.87 during midday trading on Friday, hitting $242.07. 395,797 shares of the company's stock traded hands, compared to its average volume of 442,792. The firm has a fifty day moving average price of $247.90. The company has a current ratio of 1.96, a quick ratio of 1.71 and a debt-to-equity ratio of 0.05. BeOne Medicines has a twelve month low of $142.00 and a twelve month high of $287.88. The firm has a market capitalization of $26.53 billion, a P/E ratio of -65.07 and a beta of 0.30.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. The company had revenue of $1.12 billion for the quarter, compared to analysts' expectations of $1.12 billion. As a group, equities research analysts anticipate that BeOne Medicines will post -5.82 EPS for the current fiscal year.
Insider Activity at BeOne Medicines
In other BeOne Medicines news, insider Xiaodong Wang sold 41,760 shares of the firm's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $242.66, for a total value of $10,133,481.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Chan Henry Lee sold 700 shares of the company's stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $256.11, for a total transaction of $179,277.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 203,452 shares of company stock valued at $51,856,379. Corporate insiders own 6.62% of the company's stock.
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
See Also

Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.